ES2239457T3 - Procedimiento para regular a niveles mas bajos la actividad de ligando de osteoprotegerina. - Google Patents

Procedimiento para regular a niveles mas bajos la actividad de ligando de osteoprotegerina.

Info

Publication number
ES2239457T3
ES2239457T3 ES99942778T ES99942778T ES2239457T3 ES 2239457 T3 ES2239457 T3 ES 2239457T3 ES 99942778 T ES99942778 T ES 99942778T ES 99942778 T ES99942778 T ES 99942778T ES 2239457 T3 ES2239457 T3 ES 2239457T3
Authority
ES
Spain
Prior art keywords
opgl
baselineskip
polypeptide
cell
animal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99942778T
Other languages
English (en)
Spanish (es)
Inventor
Torben Halkier
Jesper Haaning
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affitech AS
Original Assignee
Affitech AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affitech AS filed Critical Affitech AS
Application granted granted Critical
Publication of ES2239457T3 publication Critical patent/ES2239457T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Fodder In General (AREA)
ES99942778T 1998-09-15 1999-09-13 Procedimiento para regular a niveles mas bajos la actividad de ligando de osteoprotegerina. Expired - Lifetime ES2239457T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DK116498 1998-09-15
DKPA199801164 1998-09-15
US10289698P 1998-10-02 1998-10-02
US102896P 1998-10-02

Publications (1)

Publication Number Publication Date
ES2239457T3 true ES2239457T3 (es) 2005-09-16

Family

ID=26065320

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99942778T Expired - Lifetime ES2239457T3 (es) 1998-09-15 1999-09-13 Procedimiento para regular a niveles mas bajos la actividad de ligando de osteoprotegerina.

Country Status (24)

Country Link
US (2) US6645500B1 (enExample)
EP (1) EP1114166B1 (enExample)
JP (1) JP2002525060A (enExample)
KR (1) KR100671036B1 (enExample)
CN (1) CN1318105A (enExample)
AT (1) ATE291628T1 (enExample)
AU (1) AU754971B2 (enExample)
CA (1) CA2343654A1 (enExample)
CZ (1) CZ2001789A3 (enExample)
DE (1) DE69924392T2 (enExample)
EE (1) EE200100149A (enExample)
ES (1) ES2239457T3 (enExample)
HK (1) HK1040261A1 (enExample)
HR (1) HRP20010188A2 (enExample)
HU (1) HUP0103578A3 (enExample)
ID (1) ID28386A (enExample)
IL (2) IL141588A0 (enExample)
NO (1) NO20011304L (enExample)
NZ (1) NZ510508A (enExample)
PL (1) PL196790B1 (enExample)
PT (1) PT1114166E (enExample)
SK (1) SK3062001A3 (enExample)
TR (1) TR200100737T2 (enExample)
WO (1) WO2000015807A1 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9808545A (pt) * 1997-04-16 2000-05-23 Amgen Inc ácido nucleico isolado, vetor de expressão, célula hospedeira, processos para produzir uma proteìna de ligação da osteoprotegerina, para detectar a presença de uma proteìna de ligação à osteoprotegerina em uma amostra biológica, para avaliar a capacidade de um composto candidato de ligar-se a uma proteìna de ligação da osteoprotegerina e de um composto de teste para aumentar ou reduzir a ligação da proteìna de ligação da osteoprotegerina a odar, para regular a expressão de uma proteìna de ligação da osteoprotegerina em um animal e para prevenir ou tratar de doença óssea em um mamìfero, polipeptìdeo, protéina de ligação da osteroprotegerina purificada e isolada, ou seu fragmento, análogo ou derivado, e, anticorpo ou seu fragmento
US6316408B1 (en) * 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
IL141588A0 (en) * 1998-09-15 2002-03-10 M & E Biotech As Method for down-regulating osteoprotegerin ligand activity
GB9908263D0 (en) * 1999-04-13 1999-06-02 Binding Site The Limited Eliciting improved immune responses
WO2000067777A1 (en) * 1999-05-07 2000-11-16 Biofan Pty Ltd A method of prophylaxis and treatment and agents useful therefor
EP1207873B1 (en) * 1999-07-28 2009-11-18 The Trustees Of The University Of Pennsylvania Methods of inhibiting osteoclast activity
US6673771B1 (en) 1999-07-28 2004-01-06 The Trustees Of The University Of Pennsylvania Methods of inhibiting osteoclast activity
WO2001023559A1 (en) * 1999-09-27 2001-04-05 Eli Lilly And Company Osteoclast differentiation factor regulatory region
AUPQ314799A0 (en) * 1999-09-29 1999-10-21 University Of Western Australia, The Bone cell factor
JP5025871B2 (ja) * 2000-02-21 2012-09-12 エイチ．リュンドベック エイ／エス アミロイドの新規なダウン−レギュレート方法
MXPA02007796A (es) * 2000-02-21 2003-12-08 Pharmexa As Metodo novedoso para la disminucion de cuerpos amiloides.
WO2001062932A1 (en) * 2000-02-23 2001-08-30 Amgen Inc. Antagonistic selective binding agents of osteoprotegerin binding protein
US20030103978A1 (en) * 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
US20030215450A1 (en) * 2000-05-26 2003-11-20 Blake Simon M Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
WO2002015846A2 (en) * 2000-08-21 2002-02-28 Smithkline Beecham Corporation Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
JPWO2002024228A1 (ja) * 2000-09-21 2004-01-29 株式会社先端科学技術インキュベーションセンター 破骨細胞形成を制御する方法
DE60129254T2 (de) 2000-09-22 2008-03-13 Immunex Corp., Thousand Oaks Screeningverfahren für agonisten und antagonisten des rezeptoraktivators von nf-kappa b
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
EP1385532A4 (en) * 2001-03-22 2004-12-15 Barnes Jewish Hospital STIMULATION OF THE OSTEOGENESIS WITH RANG-LIGAND FUSION PROTEINS
RU2324705C2 (ru) 2001-04-03 2008-05-20 Сосьете Де Продюи Нестле С.А. Остеопротегерин, применение его для изготовления фармацевтической композиции (варианты) и получения пищевого продукта (варианты) и корма для животных, пищевой продукт, корм для животных и фармацевтическая композиция для профилактики или лечения расстройств, связанных с костным ремоделированием, и/или иммунных расстройств
ES2706902T3 (es) * 2001-06-26 2019-04-01 Amgen Inc Anticuerpos para OPGL
MY144532A (en) * 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
US20030109444A1 (en) * 2001-10-12 2003-06-12 Jonathan Lam Bone anti-resorptive compounds
JP4336467B2 (ja) * 2001-10-15 2009-09-30 株式会社林原生物化学研究所 破骨細胞形成抑制因子の産生を調節し得る物質のスクリーニング方法
EP1576088A4 (en) 2002-01-04 2006-09-06 Xencor Inc DOMINANT NEGATIVE PROTEINS AND METHOD THEREFOR
EP1560843A4 (en) * 2002-01-04 2006-09-06 Xencor Inc NEW VARIANTS OF RANKL PROTEIN
US7381792B2 (en) 2002-01-04 2008-06-03 Xencor, Inc. Variants of RANKL protein
US7718776B2 (en) * 2002-04-05 2010-05-18 Amgen Inc. Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
US6921538B2 (en) * 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
AU2003297833A1 (en) 2002-12-10 2004-06-30 Schering-Plough Ltd. Canine rankl and methods for preparing and using the same
RU2006146605A (ru) * 2004-06-02 2008-07-20 Цитос Биотехнологи Аг (Ch) Медицинские применения конъюгатов-носителей tnf-пептидов из организма кроме человека
US20080107597A1 (en) * 2006-01-12 2008-05-08 Anaptys Biosciences, Inc. Isolation of antibodies that cross-react and neutralize rankl originating from multiple species
WO2008088594A2 (en) * 2007-01-12 2008-07-24 Anaptysbio, Inc. Isolation of antibodies that cross-react and neutralize rankl orginating from multiple species
CN101434656B (zh) * 2007-11-16 2011-12-14 首都医科大学 Opg-hsp70融合蛋白的制备方法及用途
JP5866601B2 (ja) * 2008-06-18 2016-02-17 ザ テキサス エーアンドエム ユニバーシティ システムＴｈｅ Ｔｅｘａｓ Ａ＆Ｍ Ｕｎｉｖｅｒｓｉｔｙ Ｓｙｓｔｅｍ 医薬組成物の製造方法
WO2011128892A2 (en) * 2010-04-12 2011-10-20 Protea Vaccine Technologies Ltd. Modified forms of pneumococcal surface immunogenic protein b (psipb)
CN107286245B (zh) * 2016-04-11 2021-10-08 北京普纳生物科技有限公司 Pd-l1和pd-l2重组蛋白及其用途
CN107286244B (zh) * 2016-04-11 2021-10-08 北京普纳生物科技有限公司 抗免疫检查点pd-l1和pd-l2肿瘤疫苗
CN108498786A (zh) * 2018-02-13 2018-09-07 南昌大学第二附属医院 载骨保护素的缓释纳米粒及其制备方法和应用
KR102154637B1 (ko) * 2018-11-12 2020-09-10 조선대학교산학협력단 Rankl의 돌연변이체, 및 이를 포함하는 골다공증 예방 또는 치료용 약학 조성물
US20250304708A1 (en) * 2022-09-07 2025-10-02 The Regents Of The University Of California Treatment of cancer by blockade of osteoprotegerin
KR20250118303A (ko) * 2024-01-29 2025-08-06 주식회사 아크젠바이오사이온스 Rankl의 돌연변이체 및 이를 포함하는 백신 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1237764B (it) * 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
DK96493D0 (da) * 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
DE4496393T1 (de) 1993-08-27 1996-11-21 Dow Chemical Co Verfahren zur Trennung von Enantiomeren
EP0755444A4 (en) * 1994-04-01 1998-01-14 Univ Utah MOLECULAR CLONING AND EXPRESSION OF AN INDUCTIBLE PROTEASOME ACTIVATOR BY INTERFERON GAMMA
US6340459B1 (en) * 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
US6369027B1 (en) * 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
DE69738811D1 (de) * 1996-12-13 2008-08-14 Schering Corp Oberflächenantigene aus Säugern
WO1998028424A2 (en) * 1996-12-23 1998-07-02 Immunex Corporation Receptor activator of nf-kappa b, receptor is member of tnf receptor superfamily
US5843678A (en) * 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins
BR9808545A (pt) * 1997-04-16 2000-05-23 Amgen Inc ácido nucleico isolado, vetor de expressão, célula hospedeira, processos para produzir uma proteìna de ligação da osteoprotegerina, para detectar a presença de uma proteìna de ligação à osteoprotegerina em uma amostra biológica, para avaliar a capacidade de um composto candidato de ligar-se a uma proteìna de ligação da osteoprotegerina e de um composto de teste para aumentar ou reduzir a ligação da proteìna de ligação da osteoprotegerina a odar, para regular a expressão de uma proteìna de ligação da osteoprotegerina em um animal e para prevenir ou tratar de doença óssea em um mamìfero, polipeptìdeo, protéina de ligação da osteroprotegerina purificada e isolada, ou seu fragmento, análogo ou derivado, e, anticorpo ou seu fragmento
IL141588A0 (en) * 1998-09-15 2002-03-10 M & E Biotech As Method for down-regulating osteoprotegerin ligand activity

Also Published As

Publication number Publication date
AU754971B2 (en) 2002-11-28
EP1114166A1 (en) 2001-07-11
CZ2001789A3 (cs) 2001-08-15
NZ510508A (en) 2005-05-27
SK3062001A3 (en) 2002-02-05
ATE291628T1 (de) 2005-04-15
IL141588A (en) 2008-07-08
JP2002525060A (ja) 2002-08-13
PL196790B1 (pl) 2008-01-31
NO20011304L (no) 2001-05-15
HRP20010188A2 (en) 2002-04-30
TR200100737T2 (tr) 2001-07-23
DE69924392T2 (de) 2006-03-09
HUP0103578A2 (hu) 2002-01-28
CA2343654A1 (en) 2000-03-23
US20040115199A1 (en) 2004-06-17
EE200100149A (et) 2002-08-15
HUP0103578A3 (en) 2005-11-28
IL141588A0 (en) 2002-03-10
EP1114166B1 (en) 2005-03-23
WO2000015807A1 (en) 2000-03-23
CN1318105A (zh) 2001-10-17
PL346698A1 (en) 2002-02-25
KR20010085807A (ko) 2001-09-07
HK1040261A1 (zh) 2002-05-31
AU5617399A (en) 2000-04-03
KR100671036B1 (ko) 2007-01-18
NO20011304D0 (no) 2001-03-14
PT1114166E (pt) 2005-08-31
US6645500B1 (en) 2003-11-11
ID28386A (id) 2001-05-17
DE69924392D1 (de) 2005-04-28

Similar Documents

Publication Publication Date Title
ES2239457T3 (es) Procedimiento para regular a niveles mas bajos la actividad de ligando de osteoprotegerina.
KR100750695B1 (ko) Ｇｄｆ-8 활성을 하향-조절하는 방법
ES2264569T3 (es) Moleculas de tnf-alfa modificadas, adn que codifica dichas moleculas de tnf-alfa modificadas y vacunas que comprenden dichas moleculas de tnf-alfa y adn.
US20070184023A1 (en) Method for down-regulation of vegf
JP2005518194A (ja) 乱交雑ｔ細胞エピトープ挿入物を有するマルチマータンパク質の免疫原性擬態物
US20020172673A1 (en) Method for down-regulating IgE
JP2007523605A (ja) 細胞毒性が低減された免疫原性ヒトＴＮＦαアナログおよびそれらの製造方法
RS49960B (sr) Postupak za regulisanje smanjenja aktivnosti osteoprotegerinskog liganda
EP1541587A2 (en) Method for down-regulating osteoprotegerin ligand activity
WO2008040759A1 (en) Method for down-regulation of cripto
CN113318225A (zh) 肿瘤免疫增强剂及其制法和应用
KR20050052499A (ko) 자가 그렐린에 대한 면역화
HK1022918B (en) Modified tnfalpha molecules, dna encoding such modified tnfalpha molecules and vaccines comprising such modified tnfalpha molecules and dna